Lo Shiu Kwan Kan Po Ling Professorship in Pharmacy
Professor Ian Chi Kei Wong (黃志基)
B.Pharm(Hons) Sunderland UK, MSc, PhD Manchester UK
Lo Shiu Kwan Kan Po Ling Professorship in Pharmacy
- Honorary Fellow of Royal College of Paediatrics and Child Health
- Fellow of Royal Pharmaceutical Society (UK) Honorary
- Fellow of College of Pharmacy Practice (HK)
- Fellow of the Higher Education Academy (England)
- Fellow of the Academy of Life Sciences for Chinese (UK)
- Registered Pharmacist (UK & HK)
- Executive Editor of British Journal of Clinical Pharmacology
- Member of International Editorial Board of Drug Safety
- Member of International Editorial Board of Pediatric Drugs
Professor Wong is Co-Director of the Centre for Safe Medication Practice and Research ( http://www.pharma.hku.hk/sweb/CSMPR/ ) Department of Pharmacology & Pharmacy, and holder of the Lo Shiu Kwan Kan Po Ling Professorship in Pharmacy at HKU. He is Co-Director of Centre for Medication Optimisation Research and Education (CMORE) (https://www.uclh.nhs.uk/News/Pages/Pharmacycentrelaunched.aspx) at the University College London Hospital and UCL School of Pharmacy.
His expertise is in children's health, using big data research to investigate optimum use of medications for children, and formulating and producing new medications for treatment of various conditions such as epilepsy, arthritis and acute pain in young patients. As part of this work, he conducts research at Queen Mary Hospital to evaluate the safety and effectiveness of medication in patients with these and other illnesses. He is also involved in key research into medication safety, and cardiovascular and metabolic pharmacology.
Professor Wong qualified as a pharmacist in 1992 and received his PhD from The University of Manchester in 1998 for his work at the David Lewis Centre for Epilepsy. In 2002, he was appointed as the Founding Director of the Centre for Paediatric Pharmacy Research at the School of Pharmacy, University of London, and the UCL Institute of Child Health and Great Ormond Street Hospital, which is recognised as a leading research centre in medicines for children.
After joining HKU in 2011 as Head of the Department of Pharmacology & Pharmacy, Professor Wong led the accreditation of the BPharm programme by the Pharmacy and Poisons Board of Hong Kong. He was also responsible for setting up the new Master of Clinical Pharmacy programme and the CSMPR. In 2015, in addition to his work at HKU, Professor Wong took up his dual role at UCL.
Professor Wong has also advised the Departments of Health in England and Hong Kong, the World Health Organization, the European Medicines Agency, and the pharmaceutical industry. He has 220 peer-reviewed papers published in prominent journals and is an Executive Editor of British Journal of Clinical Pharmacology. Professor Wong was cited among the top 1% of scholars in the Clarivate Analytics' Essential Science Indicators in 2015, 2016 and 2017.
In recognition of his research, Professor Wong has received numerous awards for his work as an academic pharmacist. He was awarded the Chemist and Druggist Pharmacy Practice Research Conference Medal from the Royal Pharmaceutical Society of Great Britain in 2004, an Honorary Fellowship from the Royal College of Paediatrics and Child Health in the UK in 2011, an Honorary Fellowship from the College of Pharmacy Practice in Hong Kong in 2013, and a Fellowship from the Royal Pharmaceutical Society of Great Britain in 2013. He is the only pharmacist to date to have received a UK Department of Health Public Health Career Scientist Award in 2002.
Professor Wong is Vice-President of the International Society of Pharmacovigilance. He has also been an expert witness for many legal cases in the UK and Hong Kong regarding medication safety on behalf of victims of medication errors and adverse drug reactions, and for pharmaceutical companies.
Honours and Awards
- Chemist and Druggist Pharmacy Practice Research Conference Medal by Royal Pharmaceutical Society of Great Britain 2004.
- National Public Health Career Scientist Award by the Department of Health in England 2002.
- John M Harrison Award (Travel) by the UK College of Pharmacy Practice 1999.
My Research Interests
Medicines for Children
- Development of appropriate medicines for children
- Pharmaceutical care for children
- Medication errors
Pharmacoepidemiology and Drug Safety
- Methodological research
- Drug utilization
- Antiepileptic drugs
- ADHD treatment
- Antipsychotic drugs
Raman SR, Man KKC, Bahmanyar S, Berard A, Bilder S, Boukhris T, Bushnell G, Crystal S, Furu K, KaoYang YH, Karlstad Ø, Kieler H, Kubota K, Lai EC, Martikainen JE, Maura G, Moore N, Montero D, Nakamura H, Neumann A, Pate V, Pottegård A, Pratt NL, Roughead EE, Macias Saint-Gerons D, Stürmer T, Su CC, Zoega H, Sturkenbroom MCJM, Chan EW, Coghill D, Ip P, Wong ICK*.
Trends in attention-deficit hyperactivity disorder medication use: a retrospective observational study using population-based databases. Lancet Psychiatry. 2018 Oct;5(10):824-835. doi: 10.1016/S2215-0366(18)30293-1.
Impact Factor (2017/2018): 15.23
Editorials: Why are stimulant medication prescriptions rising globally?
Lau WC, Chan EW, Cheung CL, Sing CW, Man KK, Lip GY, Siu CW, Lam JK, Lee AC, Wong IC*.
Association Between Dabigatran vs Warfarin and Risk of Osteoporotic Fractures Among Patients With Nonvalvular Atrial Fibrillation. JAMA. 2017 Mar 21;317(11):1151-1158. doi: https://doi.org/10.1001/jama.2017.1363
Impact Factor(2017/2018): 47.66
Click to view:
https://jamanetwork.com/journals/jama/article-abstract/2612616 (Free download)
Man KKC, Chan EW, Ip P, Coghill D, Simonoff E, Chan PKL, Lau WCY, Schuemie MJ, Sturkenboom MCJM, Wong ICK*.
Prenatal antidepressant use and risk of attention-deficit/hyperactivity disorder in offspring: population based cohort study. BMJ. 2017 May 31;357:j2350. doi: 10.1136/bmj.j2350.
Impact Factor (2017/2018): 23.56
Click to view:
http://www.bmj.com/content/357/bmj.j2350 (open access)
Editorials. The safety of antidepressants in pregnancy BMJ 2017; 357
Man KKC, Coghill D, Chan EW, Lau WCY, Hollis C, Liddle E, Banaschewski T, McCarthy S, Neubert A, Sayal K, Ip P, Schuemie MJ, Sturkenboom MCJM, Sonuga-Barke E, Buitelaar J, Carucci S, Zuddas A, Kovshoff H, Garas P, Nagy P, Inglis SK, Konrad K, Häge A, Rosenthal E, Wong ICK*.
Association of Risk of Suicide Attempts With Methylphenidate Treatment. JAMA Psychiatry. 2017 Jul 26. doi: 10.1001/jamapsychiatry.2017.2183. [Epub ahead of print]
Impact Factor (2017/2018): 16.64
Click to view:
http://jamanetwork.com/journals/jamapsychiatry/article-abstract/2645499 (Free download)
Contribution to The National Institute for Health and Care Excellence (NICE) reports:
Attention deficit hyperactivity disorder in children and young people: guanfacine prolonged-release The National Institute for Health and Care Excellence (NICE) advice [ESNM70] Published date: March 2016 (https://www.nice.org.uk/advice/esnm70/chapter/key-points-from-the-evidence)
Guidance on The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care. The National Institute for Health and Care Excellence (NICE) 2012. (https://www.nice.org.uk/guidance/cg137)
Guidance on Attention deficit hyperactivity disorder: pharmacological and psychological interventions in children, young people and adults. The National Institute for Health and Care Excellence (NICE). 2009. (http://publications.nice.org.uk/attention-deficit-hyperactivity-disorder-cg72)
Professor Wong is the Founder and a Director of Therakind Ltd
Since Nov 2006
- In association with UCL School of Pharmacy, UCL Institute Child Health and Great Ormond Street Children’s Hospital and IPSO Ventures Professor Wong set up Therakind Ltd.
- Therakind is a commercial research organisation which works exclusively in paediatric drug research.
- The first product (Buccolam®) was granted the first “Paediatric Use Marketing Authorisation” under the new European regulation at the beginning of 2012.
- The second product (Ayendi®) was granted a product license by the Medicines and Healthcare products Agency in 2014.
- Hsia Y, Sharland M, Jackson C, Wong ICK, Magrini N, Bielicki JA.
Consumption of oral antibiotic formulations for young children according to the WHO Access, Watch, Reserve (AWaRe) antibiotic groups: an analysis of sales data from 70 middle-income and high-income countries. Lancet Infect Dis. 2019 Jan;19(1):67-75.
Impact factor (2017/2018): 25.14
- Hayes JF, Lundin A, Wicks S, Lewis G, Wong ICK, Osborn DPJ, Dalman C.
Association of Hydroxylmethyl Glutaryl Coenzyme A Reductase Inhibitors, L-Type Calcium Channel Antagonists, and Biguanides With Rates of Psychiatric Hospitalization and Self-Harm in Individuals With Serious Mental Illness. JAMA Psychiatry. 2019 Jan 9. doi: 10.1001/jamapsychiatry.2018.3907.
https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2719703 (Free download)
Impact factor (2017/2018): 16.64
- Law SWY, Lau WCY, Wong ICK, Lip GYH, Mok MT, Siu CW, Chan EW.
Sex-Based Differences in Outcomes of Oral Anticoagulation in Patients With Atrial Fibrillation. J Am Coll Cardiol. 2018 Jul 17;72(3):271-282. doi: 10.1016/j.jacc.2018.04.066.
Impact factor (2017/2018): 16.83
- Leung WK, Wong IO, Cheung KS, Yeung KF, Chan EW, Wong AY, Chen L, Wong IC, Graham DY.
Effects of Helicobacter PYLORI Treatment on Incidence of Gastric Cancer in Older Individuals. Gastroenterology. 2018 Mar 14. pii: S0016-5085(18)30322-6.
https://www.gastrojournal.org/article/S0016-5085(18)30322-6/fulltext (Free download)
Impact factor (2017/2018): 20.87
- Cheung KS, Chan EW, Wong AYS, Chen L, Wong ICK, Leung WK.
Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study. Gut. 2018 Jan;67(1):28-35.
http://gut.bmj.com/content/67/1/28 (Free download)
Impact factor (2017/2018):17.01
* Corresponding author
Selected Successful External Grants in Hong Kong:
- Wong ICK, Cheung L, Pirmohamed M, Carlton B, Sham PC, Chan CYJ, Cheung BMY. Pharmacogenomics Assessment of Serious Cutaneous Adverse drug reactions (PASCA). Health and Medical Research Fund Department of Health Hong Kong (HK$910,000) 2014-2016.
- Wong ICK, Douglas I, Ip P, Wong WWS, Coghill D. ADHD Treatments and Hospital Accident and emergency attendance aNalysis (ATHAN). Research Grant Council. Hong Kong Government (HK$308,855) 2013-2014.
- Wong ICK, McGhee S, Tse VC, Kwan M, Wong C, Ip D, Chui J. Mother's preferences and willingness to pay for human papillomavirus vaccination for their daughters: a discrete choice experiment in Hong Kong. Health and Medical Research Fund Department of Health Hong Kong (HK$ 378,040) 2013-2015
- Wong ICK, Deferiprone Evaluation in Paediatrics (DEEP) HK$200,000 (20,000€) European Commission FP7 grant via Universitätsklinikum Erlangen. 2011 -2014
- Wong ICK, Global Research in Paediatrics (GRiP) HK$ 500,000 (50,000€) European Commission FP7 grant via University College London 2011 – 2015
- Yuen VMY, Cheuk KLD, Lam WWM, Hui WCT, ICK Wong, Irwin MG. Comparison of oral chloral hydrate and intranasal dexmedetomidine for sedation in children undergoing computerized tomography. Health and Medical Research Fund, Department of Health Hong Kong (HK$ 755,840) 2013-2014.
- Lam MPS, Cheung BMY, Wong ICK. An evaluation of the prescribing appropriateness of Hong Kong elderly and the prevalence of preventable drug related admissions to hospital. Health and Medical Research Fund, Department of Health Hong Kong (HK$ 69,990) 2013.
- Wong ICK, Chan EWY. Scoping exercise: Pharmaceutical Services of Elderly Patients in Hong Kong. Pharmaceutical Society of Hong Kong. (HK$ 70,000) 2012-2013.
- Wong ICK. Impact of Prevenar on the burden of disease due to otitis media in children. St George's Medical School London. (HK$470,000) 2011-2012.
- Wong ICK, Lam JKW. Feasibility study of transmucosal formulation of a paediatric medication. Jacobson Pharmaceutical Company. 2012-2013 (HK$180,000).
- Wong ICK, Chan EWY. Feasibility study of HerbMiners Database. HerbMiners. (HK$120,000) 2012-2013.
- Chan EW, Worsley A, Wong ICK. Pharmacoepidemiology and pharmacoeconomics of oral anticoagulation therapy in Hong Kong. Pfizer and BMS Pharmaceuticals. (HK$ 898,698) 2013-2014
- Chan EW, Wong ICK. Young adult patient experiences in the clinical management of ADHD in Hong Kong. Johnson & Johnson (HK) Ltd (HK$300,000) 2013-2014.
- Institute of Child Health, University College London. Professor Deborah Christie, Professor Alastair Sutcliffe and Professor Russell Viner.
- Institute of Psychiatry, King’s College London. Professor Emily Simonoff.
- Global Research in Pediatrics (GRIP) European Network of Excellence.
- Asian Pharmacoepidemiology Network (AsPEN).
- Attention deficit/hyperactivity disorder drugs use chronic effects (ADDUCE) Consortium
Seeking PhD candidates
We are seeking highly organised and motivated PhD candidates for research in the areas of medication safety, pharmacoepidemiology and pharmaceutical care in children and the elderly. Candidates with a background in healthcare may have an advantage, however it is not a requirement. For further information, please email Prof Ian Wong with your CV (email: email@example.com).
Selected media releases and communications
Treatment of psychiatric illness:
(Oriental Daily Chinese)
(Apple Daily Chinese)
(BBC Website English)
(BBC Website English)
(Guardian Newspaper English)
(Guardian Newspaper English)
(BBC website English)
Public seminar on immunization:
2/F, 21 Sassoon Road, Li Ka Shing Faculty of Medicine, Laboratory Block, Faculty of Medicine Building, Hong Kong SAR, China